Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET

Company Participants

Andrew McKibben - Vice President, Investor Relations
Chris Peetz - Chief Executive Officer
Peter Radovich - President & Chief Operating Officer
Joanne Quan - Chief Medical Officer
Eric Bjerkholt - Chief Financial Officer

Conference Call Participants

Jon Wolleben - Citizens JMP
Steven Seedhouse - Raymond James
David Lebowitz - Citi
Mike Ulz - Morgan Stanley
Jessica Fye - JPMorgan
Gavin Clark-Gartner - Evercore ISI
Mani Foroohar - Leerink Partners
Dae Gon Ha - Stifel

Operator

Good afternoon, everyone, and welcome to the Mirum Pharmaceuticals reports Second Quarter 2024 Financial Results and provides Business Update. My name is Carla, and I will be coordinating your call today. [Operator Instructions] I will now hand you over to Andrew McKibben, Vice President of Investor Relations and Finance, to begin. Andrew, please go ahead.

Andrew McKibben

Thanks, Carla, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals Second Quarter 2024 Conference Call. I'm joined today by our CEO, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; our Chief Medical Officer, Joanne Quan; and Eric Bjerkholt, our Chief Financial Officer.

Earlier today, Mirum issued a news release announcing the company's results for the second quarter of 2024. Copies of this news release and SEC filings can be found in the Investors section of our website.

Before we start, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements based on management's current expectations, including statements regarding Mirum's programs and market opportunities for its approved medicines and product candidates. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. We are under no duty to update these statements. Please refer to the risk factors in our latest Form 10-Q and subsequent SEC filings for more information.

With that said, I'd like to turn the call over to Chris. Chris?

Chris Peetz

Thanks, Andrew, and good afternoon to everyone. I'm excited to share with you the outstanding progress we've made in this quarter with our commercial medicines and pipeline. It's been a strong quarter across the board with continued growth, important regulatory achievements and positive volixibat interim results.

On the commercial side, adoption of our medicines continues to grow with total net product sales of $77.8 million across LIVMARLI, CHENODAL and CHOLBAM, representing a 139% increase from the second quarter of last year. Building on the strength, we've also achieved important regulatory milestones for our commercial medicines. We submitted our NDA for chenodiol in CTX, which, if approved, will allow us to take additional steps to reach this underdiagnosed population and provide an opportunity for orphan exclusivity.